and the CS/GS Combined Therapy Study Group
Objective. To assess the efficacy and safety of combination therapy with chondroitin sulfate (CS) and glucosamine sulfate (GS) compared to placebo in patients with symptomatic knee osteoarthritis (OA).
Methods. A multicenter, randomized, double-blind, placebo-controlled study was performed in 164 patients with Kellgren/Lawrence grade 2 or grade 3 radiographic knee OA and moderate-to-severe knee pain (mean 6 SD global pain score 62.1 6 11.3 mm on a 100-mm visual analog scale [VAS] ). Patients were randomized to receive either combined treatment with CS (1,200 mg) plus GS (1,500 mg) or placebo in a single oral daily dose for 6 months. The mean change from baseline in the VAS global pain score was set as the primary end point. Secondary outcomes included the mean change in the investigator's global assessment of disease activity, total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), pain and function subscale scores on the WOMAC, responder rates based on the Outcome Measures in Rheumatology (OMERACT)-Osteoarthritis Research Society International (OARSI) 2004 response criteria, and rescue medication use. Adverse events were also recorded. A Data and Safety Monitoring Board was instituted to ensure patient safety and data accuracy.
Results. Intriguingly, in the modified intent-to-treat (mITT) population, CS/GS combination therapy was inferior to placebo in the reduction of joint pain (mean 6 SD change in VAS global pain score over 6 months 211.8 6 2.4 mm [19% reduction] in patients receiving CS plus GS versus 220.5 6 2.4 mm [33% reduction] in patients receiving placebo; peak between-group difference in global pain score at 6 months 8.7 mm [14.2%], P < 0.03), but no between-group differences were seen in the per-protocol completers. Both placebo treatment and CS/GS combination treatment improved to a similar extent the total WOMAC score as well as the pain and function WOMAC subscale scores, both in the mITT population and in the per-protocol completers. Neither the OMERACT-OARSI responder rate nor the frequency of rescue medication use differed between the treatment groups. Severe adverse events were uncommon and equally distributed.
Conclusion. The results of this trial demonstrate a lack of superiority of CS/GS combination therapy over placebo in terms of reducing joint pain and functional impairment in patients with symptomatic knee OA over 6 months. Further research might fully elucidate the suitability of CS/GS combination therapy in patients with OA.
Osteoarthritis (OA) of the knee is a prevalent chronic disorder characterized by progressive joint deterioration that results in disabling symptoms in ;10% of individuals older than age 55 years (1) . Guidelines for the treatment of knee OA include weight loss, muscle strengthening, and analgesic/antiinflammatory drugs. Nonsteroidal antiinflammatory drugs (NSAIDs), paracetamol, and opioids are the most frequently prescribed medications in daily clinical practice, although long-term consumption of these drugs is associated with a high incidence of side effects (2) (3) (4) (5) . Indeed, NSAID use may increase the risk of gastrointestinal adverse events, heart attacks, and acute renal failure. In addition, comorbidities may hinder NSAID use in some patients, leading to treatment with opioids instead. In turn, opioids are thought to increase the risk of fracture and the likelihood of poor self-reported health outcomes. Joint replacement surgery remains the best therapeutic option in severe cases.
In spite of the great controversy surrounding the use of symptomatic slow-acting drugs in OA (SySADOAs), such as chondroitin sulfate (CS), glucosamine sulfate (GS), glucosamine hydrochloride (GH), and combination treatment with CS plus GS, these are commonly used to control symptoms of OA in Western countries. Discrepancies arise from the contradictory results that have been observed in diverse clinical trials; some points of contention include differences in chemical formulations, uneven quality of the products tested, inadequate allocation concealment, and other possible sponsor-dependent bias (6) (7) (8) (9) (10) .
CS/GS combination therapy failed to reduce joint pain in the global population of patients with knee OA from the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). However, in a subset analysis that had not been preplanned, significant relief of joint pain was observed with this combination therapy in the subgroup of patients with moderate-to-severe knee pain (8) . The same combination therapy was shown in the head-to-head Multicentre Osteoarthritis interVEntion trial with SySADOA (MOVES) study to possess efficacy comparable to that of celecoxib for severe OA at 6 months of treatment (7) . Nevertheless, the MOVES study was regarded with criticism because it could possibly bear a large Type II error (11, 12) . Furthermore, clinical research in OA is often hindered by a considerably high placebo effect, in particular when questionnaire-based outcomes are used (13) . Therefore, the inclusion of a placebo control group appears mandatory in clinical trials involving SySADOAs (14, 15) . The aim of the present study was to assess the efficacy of CS/GS combination therapy compared to placebo after 6 months of treatment in patients with painful knee OA.
PATIENTS AND METHODS
Study design. The study was a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. It was carried out in 9 rheumatology referral centers and 1 orthopaedic surgery referral center in Spain.
The study was designed in 2 steps. In the first step, we required that 50% of the patient sample (n 5 158) would complete a study period of 6 months. Once this step had been completed, an interim analysis would be performed and the results evaluated by a Data and Safety Monitoring Board (DSMB). On the basis of the results obtained, it would be decided whether to proceed or not to proceed with the second step. In the second step, 50% of the patient sample would be recruited to complete 6 months of follow-up. Statistical analyses would be conducted on the data obtained from the total sample recruited in steps 1 and 2 (n 5 316).
Screening was followed by a baseline period in which blood was withdrawn for routine laboratory tests. In addition, radiographic studies were updated, if not available from the 3 previous months, and medications being taken for symptoms were discontinued. Throughout the screening and study periods, only acetaminophen was allowed as a rescue medication (maximum dosage 3 gm/ day), except for the 48 hours prior to clinical evaluation.
Patients were randomly assigned to 1 of the 2 treatment arms, i.e., CS plus GS or placebo. Clinic visits were scheduled at 4, 12, and 24 weeks following the baseline visit. This study was conducted for a registration dossier and was approved by the institutional review board of each participating center and by the Spanish Medicines Agency (SMA). All procedures complied with the principles of the Guidelines for Good Clinical Practice and with the Declaration of Helsinki.
Patients. The study population consisted of patients with primary symptomatic knee OA, diagnosed according to the American College of Rheumatology criteria for knee OA (16), who were classified as having radiographic grade 2 or grade 3 knee OA according to the Kellgren/Lawrence scale (17) . All recruited patients were required to have moderate-to-severe knee pain as defined by a self-reported global pain score of 40-80 mm on a 100-mm visual analog scale (VAS) during the preinclusion week. Exclusion criteria included obesity (body mass index $35 kg/m 2 ), concurrent arthritic conditions, or any coexisting disease that could preclude successful completion of the study. In those cases of bilateral knee involvement, only the most painful knee at baseline was considered.
Treatment and randomization. Patients were randomized to receive, in a single oral daily dose, a sachet of a formulation containing 1,200 mg CS (from bovine tracheal cartilage) plus 1,500 mg crystalline GS (of crustacean origin), both of which were of pharmaceutical quality (Tedec Meiji Farma), or a conveniently masked placebo. The details of the quality of the raw materials and the manufacturing process of the combination therapy were submitted and approved in advance by the SMA.
The randomization process was performed using the block randomization method, and subjects were consecutively assigned to each therapeutic group in a 1:1 ratio. The randomization was independent and computer-assisted, carried out by individuals who had no contact with the investigators who had either assigned patients to their randomized treatments or performed any patient assessment or conducted the statistical analysis. The block size was also kept secret to maintain blinding. Patients were sequentially assigned to a randomization number at each site, and the individual codes were kept in single, sealed, opaque envelopes to be opened only at the end of the study or in instances of safety concerns or a medical emergency.
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The treatment was not identified in the case report form and remained unknown until the database was closed and the results of the final analysis were reported. A patient was considered to comply with the treatment schedule when having a treatment compliance rate of $80% at each visit.
Evaluation of efficacy and safety. The primary efficacy end point was the mean reduction from baseline to end of study in the global pain score on a 0-100-mm VAS. To ascertain this score, at every visit, the patient was asked, "How much pain did you experience in your knee during the previous week?" The secondary efficacy outcomes comprised the mean reduction in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) (18) , as well as the pain and function subscale scores on the WOMAC (each on 0-100-mm VAS), the investigator's global assessment of disease activity (on 0-100-mm VAS), the percentage of treatment responders according to the Outcome Measures in Rheumatology (OMERACT)-Osteoarthritis Research Society International (OARSI) 2004 response criteria (19) , and the use of rescue medication (acetaminophen; quantified in gm/day) throughout the study.
The evaluation of treatment safety and tolerability was based on the incidence and type of adverse events (AEs). In addition, the rate of discontinuation of study treatment due to AEs was ascertained.
Establishment of the DSMB. A DSMB was instituted to ensure the ongoing safety of participants and the accurate, bias-free gathering of data (20, 21) . The DSMB was formed by a committee comprising an experienced biostatistician who prepared and presented the interim analysis prior to the first analysis, an investigator with expertise in current performance of clinical trials and clinical methodology (GH-B), and a basic researcher (RL). This committee was blinded with regard to treatment assignment and not involved in the trial procedures, and had no financial interests or conflicts of interest with the sponsor or other trial organizers.
Since this is a placebo-controlled study, it was established beforehand in the protocol to perform an interim analysis when 50% of the estimated sample size had reached the time of the 6-month follow-up. The results of the interim analysis were evaluated by the DSMB. If conclusive results were obtained, the trial would be stopped and the code broken, thereby avoiding further placebo treatments in more patients. For this interim analysis, the study results remained blinded to everyone, including the members of the DSMB.
Statistical analysis. A sufficient sample size was calculated as one that would allow for detection of differences of $10 mm in the VAS global pain score at the end of the study when comparing mean values between treatment groups. Based on certain assumptions, including a standard deviation of 30 points, a global alpha error of 0.05, and a beta error of 0.2 (80% power), the number of evaluable patients to be included was 125 per treatment arm. With a 20% dropout rate, the final sample size considered was 316 patients (158 per treatment arm).
The interim analysis was carried out when 158 patients (50% of the total sample) had completed the first step of the study period as planned. To conduct this analysis, the alpha error was readjusted to 0.03 and the necessary sample size was adjusted to 79 patients per treatment arm, in accordance with the Pocock approach (22) . It was established that an alpha error of ,0.0307 would lead to a DSMB recommendation that the trial be ended. Likewise, for an alpha value of .0.0307, the DSMB would recommend that the trial be either continued or stopped for lack of efficacy.
The analysis populations were defined a priori as follows: 1) modified intent-to-treat (mITT) population, consisting of all randomized patients who received at least one dose of the study treatment and who had at least one postbaseline assessment of the main variable; 2) per-protocol population, consisting of all patients in the mITT population who were without major protocol deviations; and 3) safety population, made up of all randomized patients who received at least one dose of the study treatment.
In this study, the mixed model for repeated measures (MMRM) method was used in order to impute the missing values for the efficacy analysis. Absolute change from baseline was calculated for each visit without imputing any missing values, before the MMRM model was applied. Subsequently, the MMRM analysis was performed by including in the model the absolute change from baseline as the dependent variable, treatment group as the independent variable, patient as the random variable, and visit as the repeated measure. Thus, the MMRM model was used to calculate a predicted value for each missing value. After this imputation process had been carried out, the MMRM model yielded estimates for the dependent variable and P values for comparisons between treatments. The same process was performed for the relative change from baseline.
Continuous variables were summarized using the mean 6 SD. The Shapiro-Wilk test was used for comparisons between groups when the continuous measure followed a normal distribution, and Levene's test was carried out to confirm the homogeneity. Categorical variables were summarized in contingency tables by presenting the number and percentage of subjects in each category. The 95% confidence interval (95% CI) for each categorical variable was included in the efficacy analysis tables. For continuous variables, comparisons between treatments were done using the parametric Student's t-test when the variable followed a normal distribution, and the nonparametric Wilcoxon's test when it did not. Where applicable, the chi-square test or Fisher's exact test was performed to analyze the relationships between categorical variables and treatments.
After checking the assumptions of normality, homoscedasticity, and parallelism, the comparison of continuous variables between treatments (A versus B) was performed using a parametric analysis of covariance (ANCOVA) model for the sensitivity analysis. Continuous variables (i.e., global pain scores) were taken as explanatory variables. Treatment was the explicative variable, and the baseline value was included as a covariate. To test the influence of rescue medication, a second ANCOVA model was constructed to include treatment, baseline VAS global pain score, and rescue medication use.
For the difference between treatments, the mean values and corresponding 95% CIs were calculated. All analyses were undertaken using SAS for Windows, version 9.3 (SAS Institute).
RESULTS
Disposition and demographic characteristics of the patients. Of the 193 patients with knee OA who were screened, 85.0% (n 5 164) were randomized to a treatment group and included in the ITT population. Among all patients who were included in the ITT analysis, 96.3% (n 5 158) were eligible for the mITT population ( Figure 1 ). In total, 18% of patients in the placebo group compared with 31% of patients receiving CS plus GS failed to complete the 6-month treatment period in compliance with the terms established by the study protocol (Figure 1) . Although no significant difference was observed, the CS/GS combination therapy group had a higher number of dropouts (mainly due to AEs and protocol deviations) compared to the placebo group (Figure 1) . The median time to dropout in both groups was similar: median 12.0 weeks (interquartile range 8.1-13.4) in patients receiving CS plus GS and 11.5 weeks (interquartile range 5.1-13.0) in patients receiving placebo.
The demographic and clinical characteristics of the patients with knee OA in the mITT population were comparable at baseline in both groups (Table 1 ). All recruited patients had moderate-to-severe symptomatic knee OA, with a mean 6 SD VAS global pain score of 62.1 6 11.3 mm at baseline. The rate of compliance was 94.3%.
Efficacy results. The efficacy data were analyzed in a blinded manner. It is important to remember that the DSMB could stop the trial and break the study code if significant differences in the primary end point between the 2 treatment arms were evident at the time of the interim analysis. Indeed, at this interim time point, in the mITT population, there was a mean 6 SD reduction in the VAS global pain score from baseline to 6 months of 220.5 6 2.4 mm (33% reduction) in the placebo group compared to 211.8 6 2.4 mm (19% reduction) in the active treatment group. Differences in global pain scores between the 2 groups were found as early as 12 weeks after the initiation of treatment, and reached a peak difference of 8.7 mm (14.2%) at 6 months, in favor of greater reduction in pain in the placebo group (P 5 0.029) (Figure 2 ). In contrast, in Figure 1 . Disposition of patients with knee osteoarthritis in the interim analysis before the blinded randomization code was broken. ITT 5 intent-to-treat population; mITT 5 modified intent-to-treat population. the per-protocol population, the change in VAS global pain scores was similar in both groups (P 5 0.072).
No differences in any of the secondary outcome measures were observed between the groups at 6 months of treatment. Indeed, in both the mITT population and the per-protocol population, a larger decrease in the investigator's global assessment of disease activity, total WOMAC score, and pain and function WOMAC subscale scores occurred in the placebo group than in the CS plus GS group, although the differences were not statistically significant (Table 2) .
By the end of the study, ;50% of patients, both in the mITT population and in the per-protocol population, fulfilled the OMERACT-OARSI response criteria and subcriteria. The proportion of responders in the placebo group was similar to that in the CS/GS combination therapy group, both in the mITT population and in the perprotocol population (Table 3) . Furthermore, 144 patients * P values and 95% confidence intervals (95% CIs) of the differences in the percentage of responders in the chondroitin sulfate (CS) plus glucosamine sulfate (GS) group compared to the placebo group were analyzed by chi-square test. VAS 5 visual analog scale. † Statistically significant difference between groups (defined as P , 0.03).
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(91%) took acetaminophen during the study (mean 6 SD dosage 0.69 6 0.6 gm/day per patient). In the CS/GS combination therapy group, 72 patients (90%) took a rescue medication, as compared to 72 patients (92.3%) in the placebo group (P 5 0.61). The daily dosage of acetaminophen was a mean 6 SD 0.64 6 0.52 gm/day in those receiving CS plus GS and 0.73 6 0.65 gm/day in those receiving placebo. Safety results. With regard to the results of the safety analyses, the 159 patients (97%) included in the ITT population received at least one dose of the study treatment. Of these, a small number of dropouts related to AEs was reported in both groups. The incidence of dropout was higher in the CS/GS combination therapy group (Table 4) , and reasons for dropping out mainly consisted of abdominal symptoms such as diarrhea, upper abdominal pain, and constipation. There was, however, a trend toward fewer withdrawals associated with other reasons in the CS/GS combination therapy group compared to the placebo group.
DISCUSSION
This is the first randomized controlled trial sponsored by a pharmaceutical company to evaluate the efficacy of the combination of CS plus GS for the treatment of knee OA, and was the first to include a DSMB composed of independent experts charged with ensuring participant safety and accurate, bias-free data. Indeed, this independent group of experts carried out an interim analysis in adherence to preestablished criteria. Given the differences found in the primary end point between the 2 treatment arms, the blinding was broken by the DSMB, and unexpectedly, patients receiving placebo showed a greater reduction in the VAS global pain score than did patients receiving combined treatment with CS plus GS. However, the difference in pain reduction among per-protocol completers was not significant between the groups. In addition, no significant differences in secondary outcomes were observed between the 2 treatment arms, including the total WOMAC score, the pain and function subscale scores on the WOMAC, the proportion of OMERACT-OARSI responders, and the frequency of consumption of rescue medication.
Furthermore, our research is one of the few studies to investigate the efficacy and safety of CS in combination with crystalline GS, both of them of patented pharmaceutical quality. Previous evidence suggested that crystalline forms of glucosamine are more effective than other salts of glucosamine or nutraceutical supplements (23) .
Although the use of CS and GS as a treatment for joint pain has been recognized since the 1970s, limited data are available with regard to the effect of CS/GS combination therapy on knee OA. Some clinical studies have addressed the therapeutic effects of this combination on OA, especially in terms of reducing pain and improving function (7, 8, 24) . Furthermore, certain more recent studies have described a potential benefit of chondroitin plus glucosamine in modifying the structural progression of knee OA (25, 26) . However, strong criticism has been raised with regard to the design and data interpretation of these clinical and structural studies, including the lack of a placebo arm or flaws in their design (11, 12) . In contrast, other studies have failed to demonstrate a significant benefit of CS/GH combination therapy in terms of amelioration of long-term symptoms or structural damage (27) (28) (29) . In this regard, a recent 4-year follow-up study of the Osteoarthritis Initiative cohort showed that CS/GS combination treatment did not relieve symptoms or modify disease progression (30) . Of note, most of the studies with combined therapy were done with GH or with nutraceutical supplements, both being products whose effectiveness remains controversial.
Several biases in the study design and data management, which could have been introduced not only by pharmaceutical companies but also by independent authors, might have contributed to the contradictory results observed in previous randomized controlled trials (31) . The quality of the products administered, the data management, and the use of a placebo arm are some of the more substantial points of criticism (9, 27, (31) (32) (33) . In the present study, the CS (isolated from tissue of bovine origin) and the GS (obtained from a crustacean shell) were of pharmaceutical grade, thus strengthening the validity of our results. With regard to the quality of the data management, an independent DSMB was appointed before the clinical trial began, to perform an interim analysis ensuring the neutrality and reliability of the data obtained. According to the protocol, after a significant difference in pain reduction was detected in one treatment arm over the other (P 5 0.029), the DSMB advised breaking the code. Surprisingly, placebo showed greater efficacy than the active treatment in terms of reaching the primary end point at 6 months. Finally, the study was ended to prevent overexposure of additional patients to placebo treatment. This supports the appointment of external expert boards to avoid potential biases derived from sponsors.
In considering the primary end point, the effect of the placebo was higher than that of the CS/GS combination therapy in this study, albeit differences in secondary end points were not found. In OA, the placebo response itself may be important, because the results and the interpretation of the studies depend not only on the response to the active drug but also on the magnitude and direction of the response to the placebo. The placebo effect on pain and other symptoms related to OA may range from an improvement rate of 20-25% up to 60%, depending on the duration of disease, the severity of disease, and the scales used for assessment (6, 8) . In a recent meta-analysis, all interventions significantly outperformed that of oral placebo for the reduction of joint pain, with effect sizes ranging from 0.63 (95% credible interval [95% CrI] 0.39-0.88) for the most efficacious treatment (hyaluronic acid) to 0.18 (95% CrI 0.04-0.33) for the least efficacious treatment (acetaminophen). Notably, intraarticular placebo was found to have a significantly larger effect (effect size 0.29, 95% CrI 0.04-0.54) when compared to orally administered placebo (34) . These findings are consistent with those presented in a previous systematic review of all treatments used for OA (13) , and with studies that compared use of needles to use of pills for the treatment of other medical conditions (35) (36) (37) (38) . All of these findings provide a clear argument against the assessment of efficacy of CS/GS combination therapy in knee OA without a placebo control. Furthermore, our results could have been interpreted differently in the absence of a placebo arm.
It is interesting to point out that the effect size in the placebo group in our study was low, and the effect of CS plus GS was even weaker as compared to that previously reported in other studies (7) . These findings may be attributed to the fact that GS may interfere with the absorption of CS and could therefore reduce its local effect (39) . With time, our patients may have had less severe knee pain when compared to the patients in those other studies, which would justify a more attenuated effect of the pharmacologic intervention in this study. Furthermore, when the main outcome studied is particularly subjective, the placebo effect can overcome the effect of the active drug. In addition, the presence of abdominal symptoms could interfere with joint pain global assessments. The lower improvement in pain severity observed in the CS plus GS treatment group compared to the placebo group, as measured by the VAS global pain score, could be related to the higher number of patients with abdominal discomfort in the CS plus GS treatment group, thereby skewing the results in favor of more self-reported pain improvement in the placebo group.
Our study has some limitations that need to be acknowledged. The size of the study sample was small, although it was adequate to demonstrate nonsuperiority of the active treatment arm. Another confounding factor is the analgesic effect conferred by the use of a pain killer (acetaminophen) as a rescue medication, which is allowed in all OA clinical trials. Moreover, a higher number of dropouts due to AEs was detected in the CS/GS combination group, a factor that may interfere with the patient's global pain assessment. Finally, failure to meet the therapeutic goals could be attributed to the dosage regimen used in this study. Whereas the daily dose of CS and GS was administered twice per day in previous studies (7, 8) , the same total dose was administered only once daily in the current study. Nevertheless, as in our study, GS has also been administered once daily in other studies, and no difference in efficacy between CS administered once a day and CS administered in divided doses has been found (40) . Thus, our results cannot be convincingly explained by differences in the dosage regimen used.
In summary, our findings show that CS/GS combination therapy was not superior to placebo in controlling pain and functional limitation in patients with knee OA at 6 months of treatment. Further preclinical and clinical research may provide valuable insights into the efficacy of combined treatment with CS plus GS as a therapeutic option in patients with OA.
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